

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FIFTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM FEBRUARY 1, 2020 THROUGH FEBRUARY 29, 2020**

Name of Applicant:

FTI Consulting, Inc.

Authorized to provide Professional Services  
to:

Ad Hoc Committee of Governmental and  
Other Contingent Litigation Claimants

Date of Order Approving Debtors' Payment  
of Fees and Expenses of Applicant:

December 2, 2019 [ECF No. 553]

Period for which compensation and  
reimbursement is sought:

February 1, 2020 through February 29,  
2020

Monthly Fees Incurred:

\$615,089.00

1 The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$6,141.22

Total Fees and Expenses Due: \$621,230.22

This is a: X monthly \_\_\_\_ interim \_\_\_\_ final application

**PRIOR APPLICATIONS:**

Docked No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$623,033.20	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$662,060.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$641,629.20	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$619,729.60	\$11,530.84

This statement (the “Fee Statement”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “FTI”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “Committee”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “Orders”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from February 1, 2020 through and including February 29, 2020 (the “**Fifth Fee Period**”) amount to:

Professional Fees	\$615,089.00
Expenses	<u>6,141.22</u>
<b>TOTAL</b>	<b><u>\$621,230.22</u></b>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$492,071.20
Expenses at 100%	<u>6,141.22</u>
<b>TOTAL</b>	<b><u>\$498,212.42</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fifth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**

7. Detailed breakdown of the expenses incurred during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fifth Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than May 11, 2020 (the “Objection Deadline”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “Objection”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
April 27, 2020

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
Three Times Square, 10<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**SUMMARY OF HOURS BY PROFESSIONAL**  
**FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate<sup>1</sup></b>	<b>Total Hours</b>	<b>Total Fees</b>
Diaz, Matthew	Sr Managing Dir	Restructuring	\$ 1,085	66.1	\$ 71,718.50
Joffe, Steven	Sr Managing Dir	Tax	1,125	10.8	12,150.00
Simms, Steven	Sr Managing Dir	Restructuring	1,295	1.8	2,331.00
Broadhead, Gary	Managing Dir	International Healthcare	1,000	25.0	25,000.00
Knechtel, Karl	Senior Director	Restructuring	845	65.7	55,516.50
Shah, Jayshree	Senior Director	International Healthcare	930	75.0	69,750.00
Bromberg, Brian	Director	Restructuring	815	201.2	163,978.00
Suric, Emil	Director	Healthcare	735	23.8	17,493.00
Kim, Ye Darm	Consultant	Restructuring	455	182.3	82,946.50
Kurtz, Emma	Consultant	Restructuring	415	73.2	30,378.00
Limoges Friend, Alexander	Consultant	International Healthcare	625	96.8	60,500.00
Tirabassi, Kathryn	Consultant	Restructuring	455	50.9	23,159.50
Hellmund-Mora, Marili	Project Asst	Restructuring	280	0.6	168.00
<b>GRAND TOTAL</b>			<b>873.2</b>		<b>\$ 615,089.00</b>

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT B****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	7.3	\$ 3,502.50
2	Cash & Liquidity Analysis	15.4	9,776.00
7	Analysis of Domestic Business Plan	134.0	106,294.00
10	Analysis of Tax Issues	10.0	10,785.00
11	Prepare for and Attend Court Hearings	0.9	760.50
13	Analysis of Other Miscellaneous Motions	0.5	542.50
16	Analysis, Negotiate and Form of POR & DS	3.2	3,472.00
19	Case Management	2.8	2,636.00
20	General Mtgs with Debtor & Debtors' Prof	1.4	1,183.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	15.2	14,074.00
24	Preparation of Fee Application	11.2	4,991.00
28	Review of IAC Business Plan	671.3	457,072.50
<b>GRAND TOTAL<sup>1</sup></b>		<b>873.2</b>	<b>\$ 615,089.00</b>

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
1	2/3/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/4/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/5/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/7/2020	Knechtel, Karl	0.7	Review captive insurance proposal.
1	2/10/2020	Knechtel, Karl	0.4	Participate on call with the Debtors re: captive insurance.
1	2/11/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/12/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/13/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/18/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/19/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/20/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/24/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/25/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/26/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/27/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/28/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
<b>1 Total</b>			<b>7.3</b>	
2	2/13/2020	Knechtel, Karl	2.6	Review updated cash analysis.
2	2/13/2020	Knechtel, Karl	1.7	Review summary of cash flows January 2020.
2	2/13/2020	Tirabassi, Kathryn	2.6	Prepare updated cash report.
2	2/13/2020	Tirabassi, Kathryn	2.4	Continue to prepare updated cash report.
2	2/14/2020	Knechtel, Karl	0.6	Participate on call with Alix re: updated cash forecast.
2	2/14/2020	Knechtel, Karl	2.2	Review updated cash presentation.
2	2/14/2020	Tirabassi, Kathryn	0.6	Participate on call with Alix re: updated cash forecast.
2	2/14/2020	Tirabassi, Kathryn	2.1	Incorporate updates to cash report.
2	2/18/2020	Tirabassi, Kathryn	0.6	Incorporate updates to cash report.
<b>2 Total</b>			<b>15.4</b>	

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	2/3/2020	Diaz, Matthew	3.1	Participate in meeting with the Debtors to discuss the updated business plan.
7	2/3/2020	Diaz, Matthew	0.6	Review the public health initiatives.
7	2/3/2020	Diaz, Matthew	1.2	Review materials in preparation for the meeting with the Debtors on the updated business plan.
7	2/3/2020	Joffe, Steven	1.6	(Partial) Participate in meeting with the Debtors to discuss the updated business plan.
7	2/3/2020	Knechtel, Karl	1.8	Review the Debtors' revised budget.
7	2/3/2020	Knechtel, Karl	1.3	Incorporate public health initiative summary.
7	2/3/2020	Knechtel, Karl	3.1	Participate in meeting with the Debtors to discuss the updated business plan.
7	2/3/2020	Suric, Emil	3.1	Participate in meeting with the Debtors to discuss the updated business plan.
7	2/3/2020	Suric, Emil	2.9	Incorporate updates to analysis re: public health initiatives.
7	2/3/2020	Tirabassi, Kathryn	0.6	Review updated business plan presentation materials.
7	2/4/2020	Diaz, Matthew	1.2	Review the updated domestic business plan.
7	2/4/2020	Diaz, Matthew	0.4	Review the updated public health initiative analysis.
7	2/4/2020	Knechtel, Karl	2.1	Incorporate further updates to analysis re: public health initiatives.
7	2/4/2020	Knechtel, Karl	1.9	Review the revised domestic business plan.
7	2/4/2020	Suric, Emil	2.7	Incorporate updates to summary re: public health initiatives.
7	2/4/2020	Tirabassi, Kathryn	1.3	Prepare questions re: updated business plan.
7	2/4/2020	Tirabassi, Kathryn	2.1	Prepare analysis re: updated business plan.
7	2/5/2020	Diaz, Matthew	1.0	Participate on call with Houlihan to discuss the business plan and related next steps.
7	2/5/2020	Diaz, Matthew	1.6	Review the updated domestic business plan.
7	2/5/2020	Knechtel, Karl	1.0	Participate on call with Houlihan to discuss the business plan and related next steps.
7	2/5/2020	Knechtel, Karl	1.4	Update diligence request list for updated domestic budget.
7	2/5/2020	Knechtel, Karl	1.3	Review analysis re: updated domestic business plan.
7	2/5/2020	Knechtel, Karl	1.7	Review summary re: autoinjector agreement.
7	2/5/2020	Simms, Steven	0.8	Review the updated domestic business plan.
7	2/5/2020	Suric, Emil	1.0	Participate on call with Houlihan to discuss the business plan and related next steps.
7	2/5/2020	Tirabassi, Kathryn	1.0	Participate on call with Houlihan to discuss the business plan and related next steps.
7	2/6/2020	Diaz, Matthew	1.2	Participate on call with the Debtors re: autoinjector agreement.
7	2/6/2020	Diaz, Matthew	1.1	Review analysis re: updated domestic business plan.
7	2/6/2020	Diaz, Matthew	2.1	Review summary re: updated domestic business plan.
7	2/6/2020	Knechtel, Karl	1.6	Review analysis re: lease renewal.
7	2/6/2020	Knechtel, Karl	2.2	Incorporate updates to analysis re: public health initiatives.
7	2/6/2020	Knechtel, Karl	0.9	Participate on call with Houlihan re: budget analysis and diligence requests.
7	2/6/2020	Knechtel, Karl	1.2	Participate on call with the Debtors re: autoinjector agreement.
7	2/6/2020	Suric, Emil	1.2	Participate on call with the Debtors re: autoinjector agreement.
7	2/6/2020	Tirabassi, Kathryn	3.1	Prepare analysis re: updated business plan.
7	2/6/2020	Tirabassi, Kathryn	0.7	Prepare summary re: updated business plan.
7	2/7/2020	Diaz, Matthew	1.1	Review the report to the diligence sub committee re: business plan and the public health initiatives analysis.
7	2/7/2020	Knechtel, Karl	3.2	Incorporate further updates to summary re: public health initiatives.
7	2/7/2020	Knechtel, Karl	1.8	Review analysis re: updated domestic business plan.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	2/7/2020	Suric, Emil	3.2	Incorporate updates to analysis re: public health initiatives.
7	2/7/2020	Tirabassi, Kathryn	1.2	Prepare summary re: updated business plan.
7	2/7/2020	Tirabassi, Kathryn	2.9	Prepare analysis re: updated business plan.
7	2/10/2020	Diaz, Matthew	2.5	Conduct a detailed review of the analysis re: the updated domestic business plan.
7	2/10/2020	Knechtel, Karl	2.4	Incorporate updates to summary re: public health initiatives.
7	2/10/2020	Knechtel, Karl	2.6	Review analysis re: updated domestic business plan.
7	2/10/2020	Tirabassi, Kathryn	2.7	Continue to prepare updated analysis re: January 2020 business plan.
7	2/10/2020	Tirabassi, Kathryn	2.9	Prepare updated analysis re: January 2020 business plan.
7	2/10/2020	Tirabassi, Kathryn	1.2	Prepare summary re: January 2020 business plan.
7	2/11/2020	Knechtel, Karl	3.3	Review updated summary re: public health initiatives.
7	2/11/2020	Suric, Emil	2.1	Review materials in preparation for meeting with the diligence subcommittee.
7	2/12/2020	Diaz, Matthew	1.4	Review the proposed autoinjector agreement.
7	2/12/2020	Knechtel, Karl	2.2	Prepare comments re: autoinjector agreement.
7	2/12/2020	Knechtel, Karl	1.6	Review autoinjector agreement.
7	2/13/2020	Diaz, Matthew	1.9	Review the autoinjector agreement.
7	2/13/2020	Knechtel, Karl	0.6	Participate in discussion with the Debtors re: revised budget support.
7	2/14/2020	Diaz, Matthew	1.1	Conduct further review of the autoinjector agreement.
7	2/14/2020	Diaz, Matthew	1.2	Review the domestic business plan.
7	2/14/2020	Diaz, Matthew	0.7	Participate on call with counsel re: autoinjector agreement.
7	2/14/2020	Knechtel, Karl	0.7	Participate on call with counsel re: autoinjector agreement.
7	2/14/2020	Suric, Emil	2.9	Conduct a detailed review of the autoinjector agreement.
7	2/17/2020	Diaz, Matthew	0.7	Participate on call with the Debtors re: autoinjector agreement.
7	2/17/2020	Diaz, Matthew	1.5	Review summary re: autoinjector agreement.
7	2/17/2020	Diaz, Matthew	0.5	Participate on call with Houlihan re: the autoinjector agreement.
7	2/17/2020	Knechtel, Karl	2.1	Prepare comments re: autoinjector analysis.
7	2/17/2020	Tirabassi, Kathryn	3.4	Prepare analysis re: autoinjector agreement.
7	2/17/2020	Tirabassi, Kathryn	2.9	Continue to prepare analysis re: autoinjector agreement.
7	2/17/2020	Tirabassi, Kathryn	0.8	Prepare summary re: autoinjector agreement.
7	2/18/2020	Diaz, Matthew	0.5	Participate on call with counsel to prepare for the diligence subcommittee call.
7	2/18/2020	Diaz, Matthew	1.0	Participate on call with diligence subcommittee re: autoinjector agreement.
7	2/18/2020	Knechtel, Karl	3.2	Finalize autoinjector summary.
7	2/18/2020	Knechtel, Karl	1.0	Participate on call with diligence subcommittee re: autoinjector agreement.
7	2/18/2020	Knechtel, Karl	0.5	Participate on call with counsel to prepare for the diligence subcommittee call.
7	2/18/2020	Suric, Emil	1.0	Participate on call with diligence subcommittee re: autoinjector agreement.
7	2/18/2020	Tirabassi, Kathryn	2.6	Incorporate updates to analysis re: autoinjector agreement.
7	2/18/2020	Tirabassi, Kathryn	1.0	Participate on call with diligence subcommittee re: autoinjector agreement.
7	2/18/2020	Tirabassi, Kathryn	0.5	Participate on call with counsel to prepare for the diligence subcommittee call.
7	2/19/2020	Simms, Steven	0.4	Review updated analysis re: public health initiatives.
7	2/20/2020	Knechtel, Karl	0.9	Participate on call with the Debtors re: business plan support.
7	2/20/2020	Knechtel, Karl	1.1	Participate in discussion with Houlihan re: business plan review.
7	2/20/2020	Suric, Emil	1.4	Review summary re: autoinjector agreement.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	2/21/2020	Suric, Emil	1.2	Review analysis re: public health initiatives.
7	2/27/2020	Knechtel, Karl	1.3	Review updated analysis re: domestic business plan.
<b>7 Total</b>			<b>134.0</b>	
10	2/3/2020	Joffe, Steven	0.9	Review tax documents in preparation for meeting with the Debtors.
10	2/6/2020	Joffe, Steven	1.1	Review revised TSA.
10	2/6/2020	Joffe, Steven	1.0	Participate on call with tax professionals to discuss outstanding tax issues.
10	2/10/2020	Joffe, Steven	1.3	Review tax deduction memo.
10	2/12/2020	Joffe, Steven	0.5	Review letter to Committee professionals re: tax deduction memo.
10	2/13/2020	Bromberg, Brian	0.6	Review tax deduction memo.
10	2/13/2020	Bromberg, Brian	0.9	Participate in call with tax advisor group re: tax deduction memo.
10	2/13/2020	Joffe, Steven	0.9	Participate in call with tax advisor group re: tax deduction memo.
10	2/14/2020	Joffe, Steven	1.2	Review draft tax memo.
10	2/19/2020	Joffe, Steven	1.0	Participate on call with tax professionals to discuss outstanding tax issues.
10	2/27/2020	Joffe, Steven	0.6	Participate on call with tax professionals to discuss outstanding tax issues.
<b>10 Total</b>			<b>10.0</b>	
11	2/21/2020	Knechtel, Karl	0.9	Attend (telephonically) hearing re: autoinjector and lease.
<b>11 Total</b>			<b>0.9</b>	
13	2/12/2020	Diaz, Matthew	0.5	Review the KPMG retention motion.
<b>13 Total</b>			<b>0.5</b>	
16	2/3/2020	Diaz, Matthew	3.2	Participate in meeting with the Debtors to discuss the RSA.
<b>16 Total</b>			<b>3.2</b>	
19	2/10/2020	Simms, Steven	0.3	Correspond with the team re: updated domestic business plan.
19	2/12/2020	Knechtel, Karl	0.8	Review updated dataroom.
19	2/21/2020	Knechtel, Karl	1.4	Review status of outstanding requests and items posted to dataroom.
19	2/24/2020	Simms, Steven	0.3	Correspond with the team re: outstanding issues.
<b>19 Total</b>			<b>2.8</b>	
20	2/26/2020	Knechtel, Karl	1.2	Participate on call with the DOJ.
20	2/27/2020	Knechtel, Karl	0.2	Participate on call with PJT re: business plan update.
<b>20 Total</b>			<b>1.4</b>	
21	2/5/2020	Bromberg, Brian	1.5	Participate on call with the Committee to discuss the mediation motion/order, emergency relief fund, and other topics.
21	2/5/2020	Diaz, Matthew	1.5	Participate on call with the Committee to discuss the mediation motion/order, emergency relief fund, and other topics.
21	2/11/2020	Diaz, Matthew	1.9	Conduct a final review of the materials for the due diligence subcommittee meeting.
21	2/11/2020	Diaz, Matthew	0.5	Prepare for the call with the due diligence subcommittee.
21	2/11/2020	Knechtel, Karl	1.1	Participate on call with the diligence subcommittee re: revised budget and autoinjector motion
21	2/11/2020	Suric, Emil	1.1	Participate on call with the diligence subcommittee re: revised budget and autoinjector motion
21	2/11/2020	Tirabassi, Kathryn	1.1	Participate on call with the diligence subcommittee re: revised budget and autoinjector motion
21	2/12/2020	Bromberg, Brian	0.9	Participate in the Committee call to discuss the mediation motion/order, due diligence, and other topics.
21	2/12/2020	Diaz, Matthew	0.9	Participate in the Committee call to discuss the mediation motion/order, due diligence, and other topics.
21	2/12/2020	Diaz, Matthew	0.6	Prepare for the Committee call.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
21	2/12/2020	Knechtel, Karl	0.9	Participate in the Committee call to discuss the mediation motion/order, due diligence, and other topics.
21	2/19/2020	Diaz, Matthew	0.5	Participate on call with a Committee member to discuss the pending motions up for the hearing.
21	2/19/2020	Diaz, Matthew	1.0	Participate on call with the Committee to discuss the pending hearing and the mediation motion
21	2/19/2020	Joffe, Steven	0.7	(Partial) Participate on call with the Committee to discuss the pending hearing and the mediation motion
21	2/19/2020	Knechtel, Karl	1.0	Participate on call with the Committee to discuss the pending hearing and the mediation motion
<b>21 Total</b>			<b>15.2</b>	
24	2/5/2020	Tirabassi, Kathryn	0.7	Prepare December 2019 Fee Statement.
24	2/19/2020	Tirabassi, Kathryn	0.4	Prepare January 2020 Fee Statement.
24	2/20/2020	Tirabassi, Kathryn	1.2	Prepare December 2019 Fee Statement.
24	2/24/2020	Hellmund-Mora, Marili	0.6	Finalize the December 2019 Fee Statement.
24	2/25/2020	Tirabassi, Kathryn	1.5	Prepare January 2020 Fee Statement.
24	2/26/2020	Tirabassi, Kathryn	2.1	Continue to prepare January 2020 Fee Statement.
24	2/26/2020	Tirabassi, Kathryn	2.4	Prepare January 2020 Fee Statement.
24	2/27/2020	Tirabassi, Kathryn	2.3	Continue to prepare January 2020 Fee Statement.
<b>24 Total</b>			<b>11.2</b>	
28	2/2/2020	Bromberg, Brian	1.2	Review new files uploaded to dataroom.
28	2/2/2020	Kurtz, Emma	1.6	Prepare analysis re: IAC legal entities.
28	2/2/2020	Kurtz, Emma	1.3	Revise the IAC legal diligence detail to reflect updated financials.
28	2/2/2020	Kurtz, Emma	2.4	Prepare analysis re: IAC financials.
28	2/3/2020	Bromberg, Brian	1.1	Continue to review IAC financials.
28	2/3/2020	Bromberg, Brian	0.7	Coordinate Singapore trip with professionals.
28	2/3/2020	Bromberg, Brian	2.3	Review IAC financials.
28	2/3/2020	Bromberg, Brian	0.8	Coordinate Singapore diligence with other advisors.
28	2/3/2020	Bromberg, Brian	2.6	Review materials in preparation for Singapore diligence trip.
28	2/3/2020	Bromberg, Brian	3.3	Review newly provided IAC financials.
28	2/3/2020	Kim, Ye Darm	1.8	Review Canada financials.
28	2/3/2020	Kim, Ye Darm	1.4	Prepare summaries re: LAM financials.
28	2/3/2020	Kim, Ye Darm	1.9	Review product financials.
28	2/3/2020	Kim, Ye Darm	1.5	Continue to prepare analysis re: profitability.
28	2/3/2020	Kim, Ye Darm	3.1	Prepare analysis re: profitability.
28	2/3/2020	Kim, Ye Darm	1.6	Prepare analysis re: updated financials.
28	2/3/2020	Kurtz, Emma	1.7	Continue to revise IAC legal entity diligence list for Counsel.
28	2/3/2020	Limoges Friend, Alexander	3.0	Prepare analysis re: LAM financials.
28	2/3/2020	Limoges Friend, Alexander	2.0	Prepare summaries re: LAM financials.
28	2/4/2020	Broadhead, Gary	1.0	Review summaries in preparation for meetings.
28	2/4/2020	Bromberg, Brian	0.8	Participate on call with counsel re: IAC diligence.
28	2/4/2020	Bromberg, Brian	3.3	Create business plan diligence outline.
28	2/4/2020	Bromberg, Brian	2.3	Review initial business plan diligence summary.
28	2/4/2020	Bromberg, Brian	2.1	Correspond with other advisors and the team re: Singapore diligence trip.
28	2/4/2020	Diaz, Matthew	1.1	Review the updated IAC analysis.
28	2/4/2020	Kim, Ye Darm	3.3	Prepare draft summaries re: financial analysis.
28	2/4/2020	Kim, Ye Darm	0.8	Participate on call with counsel re: IAC diligence.
28	2/4/2020	Kim, Ye Darm	1.9	Continue to prepare analysis re: IAC financials.
28	2/4/2020	Kim, Ye Darm	2.1	Prepare analysis re: IAC financials.
28	2/4/2020	Kurtz, Emma	0.8	Participate on call with counsel re: IAC diligence.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/4/2020	Limoges Friend, Alexander	3.2	Prepare analysis re: LAM financials.
28	2/4/2020	Limoges Friend, Alexander	1.9	Continue to prepare analysis re: LAM financials.
28	2/4/2020	Limoges Friend, Alexander	2.9	Prepare summaries in preparation for LAM meetings.
28	2/5/2020	Broadhead, Gary	1.0	Review summaries in preparation for LAM meetings.
28	2/5/2020	Bromberg, Brian	0.7	Incorporate updates to IAC diligence summary.
28	2/5/2020	Bromberg, Brian	0.5	Incorporate updates to diligence re: LAM financials.
28	2/5/2020	Bromberg, Brian	2.6	Incorporate updates to IAC diligence outline.
28	2/5/2020	Bromberg, Brian	3.4	Review business plan support.
28	2/5/2020	Bromberg, Brian	0.9	Correspond with the team re: diligence schedule.
28	2/5/2020	Bromberg, Brian	2.1	Coordinate diligence meetings with other advisors.
28	2/5/2020	Kim, Ye Darm	2.6	Prepare analysis re: IAC business plan.
28	2/5/2020	Kim, Ye Darm	2.8	Continue to prepare business plan diligence summaries.
28	2/5/2020	Kim, Ye Darm	2.4	Prepare business plan diligence summaries.
28	2/5/2020	Kim, Ye Darm	1.6	Review IAC materials received.
28	2/5/2020	Limoges Friend, Alexander	1.4	Review information received in preparation for LAM meetings.
28	2/5/2020	Limoges Friend, Alexander	2.6	Prepare analysis re: LAM financials.
28	2/6/2020	Broadhead, Gary	1.0	Review LAM materials.
28	2/6/2020	Bromberg, Brian	0.8	Review IAC summaries.
28	2/6/2020	Bromberg, Brian	3.4	Incorporate updates to business plan outline.
28	2/6/2020	Bromberg, Brian	3.3	Continue to incorporate updates to business plan outline.
28	2/6/2020	Bromberg, Brian	1.2	Correspond with other advisors re: diligence meetings.
28	2/6/2020	Bromberg, Brian	0.7	Correspond with Mundipharma counsel re: diligence meetings.
28	2/6/2020	Bromberg, Brian	0.5	Participate on call with professionals re: Dubai meetings.
28	2/6/2020	Diaz, Matthew	1.2	Review materials in preparation for meetings with the LAM executives.
28	2/6/2020	Kim, Ye Darm	1.2	Prepare summaries re: IAC products.
28	2/6/2020	Kim, Ye Darm	1.2	Review documents received from the Sacklers.
28	2/6/2020	Kim, Ye Darm	0.4	Review draft summaries for distribution.
28	2/6/2020	Kim, Ye Darm	2.9	Prepare analysis re: IAC products.
28	2/6/2020	Kim, Ye Darm	2.2	Prepare analysis re: IAC business plan.
28	2/7/2020	Broadhead, Gary	1.0	Conduct further review of LAM materials.
28	2/7/2020	Bromberg, Brian	2.1	Review updated financial documents.
28	2/7/2020	Bromberg, Brian	1.1	Review business plan summaries.
28	2/7/2020	Bromberg, Brian	2.1	Prepare internal agenda for Dubai meetings.
28	2/7/2020	Bromberg, Brian	2.8	Prepare analysis re: IAC business plan.
28	2/7/2020	Diaz, Matthew	1.9	Review questions/agendas for the call with the LAM executives.
28	2/7/2020	Kim, Ye Darm	2.4	Prepare analysis re: financials by country.
28	2/7/2020	Kim, Ye Darm	2.4	Process revisions to business plan summaries.
28	2/7/2020	Kim, Ye Darm	2.9	Prepare summaries re: LAM financials in preparation for upcoming meetings.
28	2/7/2020	Kim, Ye Darm	2.6	Prepare IAC product analysis.
28	2/7/2020	Limoges Friend, Alexander	2.9	Prepare further analysis re: LAM financial performance.
28	2/7/2020	Limoges Friend, Alexander	1.6	Prepare summaries re: LAM financial performance.
28	2/8/2020	Bromberg, Brian	0.3	Review videoconferencing capabilities for Dubai meetings.
28	2/8/2020	Kim, Ye Darm	2.6	Review LAM materials in preparation for Dubai diligence meetings.
28	2/8/2020	Kim, Ye Darm	0.6	Review LAM diligence questions for Dubai meetings.
28	2/10/2020	Broadhead, Gary	2.0	Participate in meeting with head of Consumer Health products.
28	2/10/2020	Broadhead, Gary	2.2	Participate in meeting with Chief Commercial Officer of Asia, the Middle East, and Africa.
28	2/10/2020	Broadhead, Gary	1.8	Prepare summaries re: Dubai meetings.
28	2/10/2020	Bromberg, Brian	1.8	Review diligence summaries.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/10/2020	Bromberg, Brian	1.4	Incorporate updates to IAC overview summaries.
28	2/10/2020	Bromberg, Brian	2.1	Prepare topics and agenda for upcoming Dubai meetings.
28	2/10/2020	Bromberg, Brian	1.4	Review diligence summaries to determine permissions needed to share.
28	2/10/2020	Bromberg, Brian	2.6	Create meeting summary from diligence meetings.
28	2/10/2020	Bromberg, Brian	2.0	Participate (telephonically) in meeting with head of Consumer Health products.
28	2/10/2020	Bromberg, Brian	2.2	Participate (telephonically) in meeting with Chief Commercial Officer of Asia, the Middle East, and Africa.
28	2/10/2020	Diaz, Matthew	1.5	Review the updated summaries on the IACs for the diligence subcommittee.
28	2/10/2020	Diaz, Matthew	1.1	Review the notes and related next steps coming out of the LAM meetings.
28	2/10/2020	Kim, Ye Darm	2.2	Review materials and prepare diligence questions for remaining LAM diligence calls.
28	2/10/2020	Kim, Ye Darm	1.7	Continue to process revisions to business plan summaries.
28	2/10/2020	Kim, Ye Darm	0.9	Review Houlihan update deck.
28	2/10/2020	Kim, Ye Darm	1.1	Prepare summary of diligence calls.
28	2/10/2020	Kim, Ye Darm	2.1	Process revisions to business plan summaries.
28	2/10/2020	Kim, Ye Darm	0.6	Prepare for Dubai diligence calls.
28	2/10/2020	Kim, Ye Darm	2.0	Participate (telephonically) in meeting with head of Consumer Health products.
28	2/10/2020	Kim, Ye Darm	2.2	Participate (telephonically) in meeting with Chief Commercial Officer of Asia, the Middle East, and Africa.
28	2/10/2020	Limoges Friend, Alexander	2.0	Participate (telephonically) in meeting with head of Consumer Health products.
28	2/10/2020	Limoges Friend, Alexander	2.2	Participate (telephonically) in meeting with Chief Commercial Officer of Asia, the Middle East, and Africa.
28	2/10/2020	Limoges Friend, Alexander	1.8	Continue to prepare additional analysis re: LAM financials
28	2/10/2020	Limoges Friend, Alexander	2.1	Prepare additional analysis re: LAM financials
28	2/10/2020	Limoges Friend, Alexander	0.6	Prepare summary re: LAM financials.
28	2/10/2020	Shah, Jayshree	2.0	Participate in meeting with head of Consumer Health products.
28	2/10/2020	Shah, Jayshree	2.2	Participate in meeting with Chief Commercial Officer of Asia, the Middle East, and Africa.
28	2/10/2020	Shah, Jayshree	1.8	Review materials in preparation for diligence meetings.
28	2/11/2020	Broadhead, Gary	2.3	Participate in meeting with Head of Business Development.
28	2/11/2020	Broadhead, Gary	1.8	Participate in meeting with head of the Middle East segment.
28	2/11/2020	Broadhead, Gary	1.0	Participate in meeting with LAM CFO.
28	2/11/2020	Broadhead, Gary	1.2	Participate in meeting with Chief Compliance Officer.
28	2/11/2020	Broadhead, Gary	0.7	Prepare summary re: Dubai meetings.
28	2/11/2020	Bromberg, Brian	2.8	Create IAC business plan diligence summary.
28	2/11/2020	Bromberg, Brian	1.3	Prepare call notes for LAM diligence meetings.
28	2/11/2020	Bromberg, Brian	0.8	Participate in due diligence subcommittee call re: IACs.
28	2/11/2020	Bromberg, Brian	1.3	Incorporate updates to IAC business plan diligence summaries.
28	2/11/2020	Bromberg, Brian	1.2	Create summary of LAM diligence meetings.
28	2/11/2020	Bromberg, Brian	1.2	Participate (telephonically) in meeting with Chief Compliance Officer.
28	2/11/2020	Bromberg, Brian	1.8	Participate (telephonically) in meeting with head of the Middle East segment.
28	2/11/2020	Bromberg, Brian	2.3	Participate (telephonically) in meeting with Head of Business Development.
28	2/11/2020	Diaz, Matthew	1.8	Participate (telephonically) in meeting with head of the Middle East segment.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/11/2020	Diaz, Matthew	0.8	Participate in due diligence subcommittee call re: IACs.
28	2/11/2020	Diaz, Matthew	1.8	Review the updated IAC analysis.
28	2/11/2020	Kim, Ye Darm	1.8	Participate (telephonically) in meeting with head of the Middle East segment.
28	2/11/2020	Kim, Ye Darm	2.3	Participate (telephonically) in meeting with Head of Business Development.
28	2/11/2020	Kim, Ye Darm	1.2	Participate (telephonically) in meeting with Chief Compliance Officer.
28	2/11/2020	Kim, Ye Darm	2.1	Prepare updated summaries re: IAC business plan.
28	2/11/2020	Kim, Ye Darm	1.1	Prepare LAM diligence call summaries.
28	2/11/2020	Limoges Friend, Alexander	1.8	Participate (telephonically) in meeting with head of the Middle East segment.
28	2/11/2020	Limoges Friend, Alexander	2.3	Participate (telephonically) in meeting with Head of Business Development.
28	2/11/2020	Limoges Friend, Alexander	1.2	Participate (telephonically) in meeting with Chief Compliance Officer.
28	2/11/2020	Limoges Friend, Alexander	0.9	Prepare analysis re: LAM products.
28	2/11/2020	Limoges Friend, Alexander	2.4	Prepare summaries re: LAM products.
28	2/11/2020	Shah, Jayshree	3.1	Review materials in preparation for the day's meetings with management.
28	2/11/2020	Shah, Jayshree	1.8	Participate in meeting with head of the Middle East segment.
28	2/11/2020	Shah, Jayshree	2.3	Participate in meeting with Head of Business Development.
28	2/11/2020	Shah, Jayshree	1.2	Participate in meeting with Chief Compliance Officer.
28	2/12/2020	Broadhead, Gary	1.5	Participate in meeting with the head of the China business.
28	2/12/2020	Broadhead, Gary	1.9	Participate in meeting with the head of the Australia business.
28	2/12/2020	Broadhead, Gary	1.8	Review materials in preparation for meetings.
28	2/12/2020	Broadhead, Gary	0.8	Participate in meeting with the LAM CEO and CFO.
28	2/12/2020	Bromberg, Brian	3.4	Create diligence update for Committee advisors.
28	2/12/2020	Bromberg, Brian	3.2	Continue to create diligence update for Committee advisors.
28	2/12/2020	Bromberg, Brian	0.8	Participate (telephonically) in meeting with the LAM CEO and CFO.
28	2/12/2020	Bromberg, Brian	1.5	Participate (telephonically) in meeting with the head of the China business.
28	2/12/2020	Bromberg, Brian	1.9	Participate (telephonically) in meeting with the head of the Australia business.
28	2/12/2020	Diaz, Matthew	0.6	Review the summary on the Dubai diligence meetings.
28	2/12/2020	Diaz, Matthew	1.1	(Partial) Participate (telephonically) in meeting with the head of the China business.
28	2/12/2020	Kim, Ye Darm	1.9	Prepare summary of diligence calls for internal distribution.
28	2/12/2020	Kim, Ye Darm	0.8	Participate (telephonically) in meeting with the LAM CEO and CFO.
28	2/12/2020	Kim, Ye Darm	2.2	Process revisions to business plan due diligence summaries.
28	2/12/2020	Kim, Ye Darm	2.8	Prepare additional analysis re: business plan diligence.
28	2/12/2020	Kim, Ye Darm	1.9	Continue to prepare additional analysis re: business plan diligence.
28	2/12/2020	Kim, Ye Darm	1.5	Participate (telephonically) in meeting with the head of the China business.
28	2/12/2020	Kim, Ye Darm	1.9	Participate (telephonically) in meeting with the head of the Australia business.
28	2/12/2020	Kim, Ye Darm	1.3	Continue to process revisions to business plan due diligence summaries.
28	2/12/2020	Kurtz, Emma	1.4	Prepare updated diligence request list.
28	2/12/2020	Limoges Friend, Alexander	0.8	Participate (telephonically) in meeting with the LAM CEO and CFO.
28	2/12/2020	Limoges Friend, Alexander	2.9	Prepare summaries re: updated LAM information.
28	2/12/2020	Limoges Friend, Alexander	1.5	Participate (telephonically) in meeting with the head of the China business.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/12/2020	Limoges Friend, Alexander	1.9	Participate (telephonically) in meeting with the head of the Australia business.
28	2/12/2020	Limoges Friend, Alexander	1.1	Prepare further analysis re: LAM financial performance.
28	2/12/2020	Shah, Jayshree	2.9	Review materials in preparation for meetings.
28	2/12/2020	Shah, Jayshree	0.8	Participate in meeting with the LAM CEO and CFO.
28	2/12/2020	Shah, Jayshree	1.5	Participate in meeting with the head of the China business.
28	2/12/2020	Shah, Jayshree	1.9	Participate in meeting with the head of the Australia business.
28	2/13/2020	Bromberg, Brian	0.7	Review and update request lists for diligence meeting.
28	2/13/2020	Bromberg, Brian	3.4	Provide detailed comments re: business plan summaries.
28	2/13/2020	Bromberg, Brian	0.6	Review consumer health presentation from Dubai.
28	2/13/2020	Bromberg, Brian	1.8	Continue to review updated financial documents provided in data room.
28	2/13/2020	Bromberg, Brian	2.2	Review updated financial documents provided in data room.
28	2/13/2020	Diaz, Matthew	1.2	Review open items related to IAC diligence.
28	2/13/2020	Kim, Ye Darm	2.1	Analyze IAC business plan.
28	2/13/2020	Kim, Ye Darm	2.8	Prepare additional analysis re: business plan diligence.
28	2/13/2020	Kim, Ye Darm	1.4	Continue to prepare additional analysis re: business plan diligence.
28	2/13/2020	Kim, Ye Darm	2.9	Prepare analysis re: product data.
28	2/13/2020	Kim, Ye Darm	2.6	Prepare summaries re: IAC financials.
28	2/13/2020	Kim, Ye Darm	2.6	Prepare summaries re: IAC products.
28	2/13/2020	Kurtz, Emma	2.8	Prepare updated FTI IAC diligence request list re: priority open items.
28	2/13/2020	Kurtz, Emma	0.8	Review diligence request list in response to EY report.
28	2/13/2020	Limoges Friend, Alexander	2.9	Prepare analysis re: Asia Pacific financials.
28	2/13/2020	Limoges Friend, Alexander	1.1	Prepare employee analysis re: LAM.
28	2/13/2020	Limoges Friend, Alexander	2.8	Prepare financial summaries re: LAM region.
28	2/13/2020	Limoges Friend, Alexander	2.2	Prepare financial analysis re: LAM region.
28	2/13/2020	Shah, Jayshree	3.2	Prepare overall summary re: Dubai meetings.
28	2/13/2020	Shah, Jayshree	1.9	Evaluate next steps following Dubai meetings.
28	2/13/2020	Shah, Jayshree	2.9	Continue to prepare overall summary re: Dubai meetings.
28	2/14/2020	Broadhead, Gary	2.0	Review summaries re: Dubai meetings.
28	2/14/2020	Bromberg, Brian	2.8	Create priority diligence request list following Dubai meetings.
28	2/14/2020	Bromberg, Brian	2.9	Prepare comments on business plan summaries.
28	2/14/2020	Bromberg, Brian	0.9	Participate in call with team to discuss next steps following Dubai meetings.
28	2/14/2020	Bromberg, Brian	1.7	Review the business plan summaries.
28	2/14/2020	Diaz, Matthew	3.1	Conduct a detailed review of the IAC business plan summaries.
28	2/14/2020	Kim, Ye Darm	1.6	Prepare summaries for IAC business plan.
28	2/14/2020	Kim, Ye Darm	2.1	Analyze IAC business plan.
28	2/14/2020	Kim, Ye Darm	0.9	Participate in call with team to discuss next steps following Dubai meetings.
28	2/14/2020	Kim, Ye Darm	2.3	Process further revisions to business plan summaries.
28	2/14/2020	Kurtz, Emma	0.9	Participate in call with team to discuss next steps following Dubai meetings.
28	2/14/2020	Kurtz, Emma	2.9	Continue to prepare additional summaries re: IAC business plan.
28	2/14/2020	Kurtz, Emma	2.1	Prepare additional summaries re: IAC business plan.
28	2/14/2020	Limoges Friend, Alexander	2.9	Prepare additional analysis re: IAC products.
28	2/14/2020	Limoges Friend, Alexander	1.1	Continue to prepare additional analysis re: IAC products.
28	2/14/2020	Limoges Friend, Alexander	0.9	Participate in call with team to discuss next steps following Dubai meetings.
28	2/14/2020	Limoges Friend, Alexander	3.0	Prepare analysis re: Asia Pacific financials.
28	2/14/2020	Shah, Jayshree	3.1	Prepare analysis re: Dubai meetings.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

Task Category	Date	Professional	Hours	Activity
28	2/14/2020	Shah, Jayshree	3.3	Prepare summary re: information learned in Dubai meetings.
28	2/14/2020	Shah, Jayshree	3.1	Continue to prepare summary re: information learned in Dubai meetings.
28	2/15/2020	Kim, Ye Darm	2.8	Prepare revisions to the business plan diligence summaries.
28	2/16/2020	Diaz, Matthew	2.5	Review the updated IAC business plan analysis.
28	2/17/2020	Bromberg, Brian	2.2	Prepare detailed comments re: business plan summaries.
28	2/17/2020	Bromberg, Brian	1.8	Review business plan information.
28	2/17/2020	Bromberg, Brian	1.0	Create list of partnerships of IACs.
28	2/17/2020	Bromberg, Brian	3.3	Prepare updated business plan summaries.
28	2/17/2020	Bromberg, Brian	1.9	Edit priority diligence request list following Dubai meetings.
28	2/17/2020	Kim, Ye Darm	3.2	Process edits to business plan summaries.
28	2/17/2020	Kim, Ye Darm	3.1	Continue to process edits to business plan summaries.
28	2/17/2020	Kim, Ye Darm	1.3	Prepare analysis re: IAC partnerships.
28	2/17/2020	Kim, Ye Darm	2.7	Prepare analysis re: business plan forecasts.
28	2/17/2020	Kurtz, Emma	1.2	Review updated documents received.
28	2/17/2020	Kurtz, Emma	2.3	Continue to incorporate updates to business plan summaries.
28	2/17/2020	Kurtz, Emma	2.4	Incorporate updates to business plan summaries.
28	2/17/2020	Kurtz, Emma	1.1	Prepare additional analysis re: business plan.
28	2/17/2020	Limoges Friend, Alexander	3.1	Prepare product analysis re: LAM region.
28	2/17/2020	Limoges Friend, Alexander	2.1	Continue to prepare product analysis re: LAM region.
28	2/17/2020	Limoges Friend, Alexander	2.8	Prepare summaries re: LAM product analysis.
28	2/17/2020	Shah, Jayshree	2.9	Review updated analysis re: LAM region.
28	2/17/2020	Shah, Jayshree	2.4	Continue to review updated analysis re: LAM region.
28	2/17/2020	Shah, Jayshree	2.7	Prepare detailed comments re: LAM region analysis.
28	2/18/2020	Bromberg, Brian	1.4	Review IAC financial information.
28	2/18/2020	Bromberg, Brian	2.6	Prepare additional comments re: business plan summaries.
28	2/18/2020	Bromberg, Brian	0.7	Finalize priority diligence request.
28	2/18/2020	Bromberg, Brian	1.7	Prepare further analysis re: IAC financials.
28	2/18/2020	Bromberg, Brian	2.7	Review latest version of the business plan analysis.
28	2/18/2020	Kim, Ye Darm	0.9	Prepare summary of cash balances by legal entity.
28	2/18/2020	Kim, Ye Darm	1.9	Analyze IAC business plan.
28	2/18/2020	Kim, Ye Darm	1.7	Prepare further analysis re: IAC business plan.
28	2/18/2020	Kim, Ye Darm	2.2	Prepare revisions to business plan diligence summaries.
28	2/18/2020	Kim, Ye Darm	1.8	Continue to prepare further analysis re: IAC business plan.
28	2/18/2020	Kim, Ye Darm	2.1	Continue to prepare revisions to business plan diligence summaries.
28	2/18/2020	Kurtz, Emma	2.3	Prepare updated analysis re: IAC financials.
28	2/18/2020	Kurtz, Emma	1.2	Review the IAC 2020 business plan review summary.
28	2/18/2020	Kurtz, Emma	1.6	Continue to prepare updated analysis re: IAC financials.
28	2/18/2020	Limoges Friend, Alexander	3.1	Prepare additional analysis re: IACs.
28	2/18/2020	Limoges Friend, Alexander	2.8	Continue to prepare additional analysis re: IACs.
28	2/18/2020	Limoges Friend, Alexander	2.1	Prepare additional summaries re: IACs.
28	2/18/2020	Shah, Jayshree	2.9	Prepare observations re: Asia Pacific financial performance.
28	2/18/2020	Shah, Jayshree	2.7	Continue to prepare observations re: Asia Pacific financial performance.
28	2/18/2020	Shah, Jayshree	2.4	Prepare summary re: observations on Asia Pacific financial performance.
28	2/19/2020	Bromberg, Brian	2.8	Review updated business plan summaries.
28	2/19/2020	Bromberg, Brian	2.4	Continue to review updated business plan summaries.
28	2/19/2020	Bromberg, Brian	0.5	Review DOJ meeting summary.
28	2/19/2020	Bromberg, Brian	1.7	Finalize business plan analysis.
28	2/19/2020	Bromberg, Brian	2.1	Review updated IAC files in the data room.
28	2/19/2020	Bromberg, Brian	2.2	Compile questions on business plan.
28	2/19/2020	Diaz, Matthew	2.9	Review the updated IAC analysis.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/19/2020	Kim, Ye Darm	2.1	Prepare additional analysis re: IAC business plan.
28	2/19/2020	Kim, Ye Darm	2.4	Continue to prepare additional analysis re: IAC business plan.
28	2/19/2020	Kim, Ye Darm	2.3	Prepare summaries re: business plan analysis.
28	2/19/2020	Kim, Ye Darm	1.9	Continue to prepare summaries re: business plan analysis.
28	2/19/2020	Kim, Ye Darm	2.4	Continue to prepare summaries re: business plan analysis.
28	2/19/2020	Kurtz, Emma	1.8	Prepare updates to business plan analysis.
28	2/19/2020	Kurtz, Emma	1.7	Prepare updates to business plan summaries.
28	2/19/2020	Limoges Friend, Alexander	2.8	Prepare updated LAM analysis.
28	2/19/2020	Limoges Friend, Alexander	2.7	Continue to prepare updated LAM analysis.
28	2/19/2020	Limoges Friend, Alexander	2.9	Prepare updated LAM summaries.
28	2/19/2020	Shah, Jayshree	2.1	Prepare observations re: LAM financials.
28	2/19/2020	Shah, Jayshree	1.3	Review LAM analysis.
28	2/19/2020	Shah, Jayshree	1.7	Prepare comments re: LAM analysis.
28	2/19/2020	Shah, Jayshree	2.9	Continue to prepare observations re: LAM financials.
28	2/20/2020	Bromberg, Brian	1.3	Continue to prepare additional analysis re: IAC financials.
28	2/20/2020	Bromberg, Brian	2.9	Review business plan diligence summaries.
28	2/20/2020	Bromberg, Brian	3.2	Prepare additional analysis re: IAC financials.
28	2/20/2020	Bromberg, Brian	1.7	Prepare detailed comments re: updated IAC analysis.
28	2/20/2020	Kim, Ye Darm	1.7	Process revisions to business plan diligence summaries.
28	2/20/2020	Kim, Ye Darm	1.3	Prepare analysis re: IAC business plan.
28	2/20/2020	Kim, Ye Darm	1.1	Continue to prepare analysis re: IAC business plan.
28	2/20/2020	Kim, Ye Darm	1.9	Continue to process revisions to business plan diligence summaries.
28	2/20/2020	Kim, Ye Darm	1.4	Continue to process revisions to business plan diligence summaries.
28	2/20/2020	Kim, Ye Darm	1.3	Continue to prepare analysis re: IAC business plan.
28	2/20/2020	Kurtz, Emma	3.4	Incorporate updates to business plan analysis.
28	2/20/2020	Kurtz, Emma	1.2	Continue to incorporate updates to business plan analysis.
28	2/20/2020	Limoges Friend, Alexander	2.4	Review updated files in dataroom.
28	2/20/2020	Limoges Friend, Alexander	1.6	Review LAM analysis.
28	2/20/2020	Shah, Jayshree	2.0	Prepare detailed comments re: LAM region analysis.
28	2/21/2020	Bromberg, Brian	0.7	Prepare update re: status of IAC business plan diligence.
28	2/21/2020	Bromberg, Brian	3.2	Review updated business plan diligence summaries.
28	2/21/2020	Bromberg, Brian	0.6	Participate in call with Company advisors re: diligence.
28	2/21/2020	Bromberg, Brian	0.7	Participate in call with Houlihan re: IAC workplan and business plan diligence.
28	2/21/2020	Bromberg, Brian	1.3	Review materials in preparation for call with Company advisors.
28	2/21/2020	Bromberg, Brian	0.8	Review materials in preparation for call with Houlihan.
28	2/21/2020	Bromberg, Brian	2.7	Continue to review updated business plan diligence summaries.
28	2/21/2020	Kim, Ye Darm	1.8	Process edits to business plan summaries.
28	2/21/2020	Kim, Ye Darm	2.6	Review analyst reports re: pharmaceutical market macroeconomic trends.
28	2/21/2020	Kim, Ye Darm	2.3	Continue to process edits to business plan summaries.
28	2/21/2020	Kurtz, Emma	1.3	Review updated documents received.
28	2/21/2020	Kurtz, Emma	0.8	Prepare additional analysis re: business plan.
28	2/21/2020	Kurtz, Emma	0.6	Participate in call with Company advisors re: diligence.
28	2/21/2020	Kurtz, Emma	0.7	Participate in call with Houlihan re: IAC workplan and business plan diligence.
28	2/21/2020	Shah, Jayshree	0.6	Participate in call with Company advisors re: diligence.
28	2/24/2020	Bromberg, Brian	3.3	Prepare detailed comments re: business plan summaries.
28	2/24/2020	Bromberg, Brian	3.2	Incorporate updates to business plan summaries.
28	2/24/2020	Bromberg, Brian	1.2	Continue to incorporate updates to business plan summaries.
28	2/24/2020	Bromberg, Brian	1.3	Review business plan diligence documents.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	2/24/2020	Kim, Ye Darm	1.7	Continue to prepare analysis re: business plan diligence.
28	2/24/2020	Kim, Ye Darm	1.2	Prepare diligence question follow up list for Steve Jamieson re: financial support files.
28	2/24/2020	Kim, Ye Darm	1.3	Continue to prepare analysis re: business plan diligence.
28	2/24/2020	Kim, Ye Darm	2.9	Prepare analysis re: business plan diligence.
28	2/24/2020	Kurtz, Emma	2.2	Incorporate comments to business plan analysis.
28	2/24/2020	Kurtz, Emma	1.6	Continue to incorporate comments to business plan analysis.
28	2/25/2020	Bromberg, Brian	2.3	Prepare comments re: business plan analysis.
28	2/25/2020	Bromberg, Brian	1.5	Prepare questions for call with management.
28	2/25/2020	Bromberg, Brian	3.2	Incorporate updates to business plan analysis.
28	2/25/2020	Bromberg, Brian	3.1	Review business plan analysis.
28	2/25/2020	Kim, Ye Darm	3.2	Prepare detailed QC of business plan diligence summaries.
28	2/25/2020	Kim, Ye Darm	1.9	Review updated business plan summaries.
28	2/25/2020	Kim, Ye Darm	2.3	Incorporate updates to business plan summaries.
28	2/25/2020	Kurtz, Emma	2.3	Incorporate comments to business plan analysis.
28	2/25/2020	Kurtz, Emma	2.6	Continue to incorporate comments to business plan analysis.
28	2/25/2020	Kurtz, Emma	0.4	Prepare updated summaries re: IAC business plan.
28	2/26/2020	Bromberg, Brian	2.6	Prepare additional comments re: business plan summaries.
28	2/26/2020	Bromberg, Brian	2.4	Edit question list for management call.
28	2/26/2020	Bromberg, Brian	3.4	Review updated business plan summaries.
28	2/26/2020	Bromberg, Brian	1.1	Continue to prepare additional comments re: business plan summaries.
28	2/26/2020	Diaz, Matthew	2.1	Review the updated IAC analysis.
28	2/26/2020	Kim, Ye Darm	2.9	Process revisions to the business plan diligence summaries.
28	2/26/2020	Kim, Ye Darm	0.9	Update diligence question list.
28	2/26/2020	Kim, Ye Darm	2.1	Continue to process revisions to the business plan diligence summaries.
28	2/26/2020	Kim, Ye Darm	2.4	Prepare additional analysis re: IACs.
28	2/26/2020	Kim, Ye Darm	2.2	Continue to prepare additional analysis re: IACs.
28	2/26/2020	Kurtz, Emma	2.6	Analyze pharmaceutical industry trend information.
28	2/26/2020	Limoges Friend, Alexander	1.0	Incorporate comments to IAC analysis.
28	2/26/2020	Shah, Jayshree	0.5	Review updated IAC analysis.
28	2/27/2020	Bromberg, Brian	1.9	Prepare question list for management.
28	2/27/2020	Bromberg, Brian	1.1	Incorporate updates to business plan summaries.
28	2/27/2020	Bromberg, Brian	2.1	Edit volume request for management.
28	2/27/2020	Bromberg, Brian	2.8	Review cash flow statements and balance sheets provided in dataroom.
28	2/27/2020	Diaz, Matthew	1.7	Review the updated IAC analysis.
28	2/27/2020	Kurtz, Emma	1.2	Revise question list prepared for call with management.
28	2/27/2020	Kurtz, Emma	3.4	Prepare updated IAC analysis.
28	2/27/2020	Kurtz, Emma	3.3	Continue to prepare updated IAC analysis.
28	2/28/2020	Bromberg, Brian	0.7	Edit request for historical data.
28	2/28/2020	Bromberg, Brian	2.2	Review consumer health vendor due diligence.
28	2/28/2020	Bromberg, Brian	2.6	Review updated IAC documents provided.
28	2/28/2020	Bromberg, Brian	2.2	Participate in call with management re: financial diligence.
28	2/28/2020	Diaz, Matthew	1.5	Review open items and due diligence lists on the IAC review.
28	2/28/2020	Kurtz, Emma	2.2	Participate in call with management re: financial diligence.
28	2/28/2020	Kurtz, Emma	2.1	Incorporate further updates to IAC business plan analysis.
28	2/28/2020	Kurtz, Emma	0.4	Prepare detailed summary notes of call with management.
28	2/28/2020	Kurtz, Emma	0.4	Prepare updated analysis re: IAC business plan.
28	2/28/2020	Limoges Friend, Alexander	1.3	Review updated documents added to the dataroom.
28	2/28/2020	Limoges Friend, Alexander	2.2	Participate in call with management re: financial diligence.
28	2/28/2020	Shah, Jayshree	2.2	Participate in call with management re: financial diligence.

**EXHIBIT C****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

Task Category	Date	Professional	Hours	Activity
28	2/28/2020	Shah, Jayshree	0.7	Prepare updated data request list.
28	2/28/2020	Shah, Jayshree	3.2	Review updated IAC financial analysis.
28	2/28/2020	Shah, Jayshree	2.8	Review updated documents added to the dataroom.
<b>28 Total</b>			<b>671.3</b>	
<b>Grand Total</b>			<b>873.2</b>	

**EXHIBIT D****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF EXPENSES****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

<b>Expense Type</b>	<b>Amount</b>
Airfare	\$ 1,778.00
Lodging	3,411.55
Transportation	416.98
Working Meals <sup>1</sup>	534.69
<b>Grand Total<sup>2</sup></b>	<b>\$ 6,141.22</b>

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

2. Expenses incurred internationally have been translated to USD using the relevant spot rate.

**EXHIBIT E****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****EXPENSE DETAIL****FOR THE PERIOD FEBRUARY 1, 2020 TO FEBRUARY 29, 2020**

Date	Professional	Expense Type	Expense Detail	Amount
2/9/2020	Broadhead, Gary	Airfare	Airfare - Coach Equivalent, Gary Broadhead, LHR - DXB, 02/09/2020 - 02/13/2020. Airfare to Dubai for client meetings.	\$ 889.00
2/9/2020	Shah, Jayshree	Airfare	Airfare - Coach Equivalent, Jayshree Shah, LHR - DXB, 02/09/2020 - 02/12/2020. Airfare to Dubai for client meetings.	889.00
<b>Airfare Total</b>				<b>\$ 1,778.00</b>
2/9/2020	Broadhead, Gary	Lodging	Lodging - Gary Broadhead 02/09/2020 - 02/13/2020. Hotel stay while in Dubai for client meetings.	1,959.39
2/9/2020	Shah, Jayshree	Lodging	Lodging - Jayshree Shah 02/09/2020 - 02/12/2020. Hotel stay while in Dubai for client meetings.	1,452.16
<b>Lodging Total</b>				<b>\$ 3,411.55</b>
1/15/2020	Simms, Steven	Transportation	Taxi home after working late on the case.	75.41
1/22/2020	Bromberg, Brian	Transportation	Taxi home after working late on the case.	24.37
2/4/2020	Bromberg, Brian	Transportation	Taxi home after working late on the case.	21.57
2/6/2020	Bromberg, Brian	Transportation	Taxi home after working late on the case.	22.54
2/7/2020	Bromberg, Brian	Transportation	Taxi home after working late on the case.	19.29
2/9/2020	Broadhead, Gary	Transportation	Taxi to the airport while traveling for client meetings.	32.20
2/10/2020	Broadhead, Gary	Transportation	Taxi to the hotel while traveling for client meetings.	17.37
2/10/2020	Broadhead, Gary	Transportation	Taxi to meeting while traveling for client meetings.	20.28
2/10/2020	Broadhead, Gary	Transportation	Taxi to meeting while traveling for client meetings.	7.68
2/10/2020	Broadhead, Gary	Transportation	Taxi to the hotel while traveling for client meetings.	8.46
2/11/2020	Shah, Jayshree	Transportation	Taxi to meeting while traveling for client meetings.	17.05
2/11/2020	Shah, Jayshree	Transportation	Taxi to meeting while traveling for client meetings.	22.18
2/12/2020	Broadhead, Gary	Transportation	Taxi to meeting while traveling for client meetings.	21.14
2/13/2020	Broadhead, Gary	Transportation	Taxi to the airport while traveling for client meetings.	45.38
2/13/2020	Broadhead, Gary	Transportation	Taxi to the hotel while traveling for client meetings.	16.54
2/13/2020	Shah, Jayshree	Transportation	Taxi to meeting while traveling for client meetings.	7.25
2/13/2020	Shah, Jayshree	Transportation	Taxi to meeting while traveling for client meetings.	8.98
2/18/2020	Kurtz, Emma	Transportation	Taxi home after working late on the case.	11.54
2/27/2020	Kurtz, Emma	Transportation	Taxi home after working late on the case.	17.75
<b>Transportation Total</b>				<b>\$ 416.98</b>
1/2/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/2/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
1/3/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/6/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/6/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
1/6/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
1/7/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/7/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
1/7/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
1/8/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/8/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
1/9/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/9/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
1/21/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/21/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
1/22/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/3/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/3/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/5/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/6/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/6/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/7/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	18.04
2/10/2020	Broadhead, Gary	Working Meals	Dinner while traveling for meetings (2 participants).	40.00
2/11/2020	Shah, Jayshree	Working Meals	Lunch while traveling for meetings (2 participants).	36.65
2/13/2020	Shah, Jayshree	Working Meals	Lunch while traveling for meetings.	20.00
<b>Working Meals Total</b>				<b>\$ 534.69</b>
<b>Grand Total</b>				<b>\$ 6,141.22</b>

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

2. Expenses incurred internationally have been translated to USD using the relevant spot rate.